Clinical Trial: A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06976190) titled 'A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma' on May 08.

Brief Summary: This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Recurrent or Metastatic Nasopharyngeal Carcinoma

Intervention: DRUG: MRG003 + Pucotenlimab

MRG003 will be administrated as specified in the protocol. Pucoten...